Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (NASDAQ: PSTV) generates a steady flow of news as a clinical-stage pharmaceutical and healthcare company focused on targeted radiotherapeutics and precision diagnostics for central nervous system (CNS) cancers. Headquartered in Houston, Texas, the company regularly reports on its clinical trial progress, regulatory interactions, capital markets activity, and expansion of its CNSide Diagnostics subsidiary.
News about Plus Therapeutics often highlights developments related to REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational radiotherapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Updates include clinical data presentations at major oncology meetings, safety and efficacy findings from the ReSPECT-GBM and ReSPECT-LM trials, and discussions with the U.S. Food and Drug Administration (FDA) on pivotal trial design and potential accelerated approval pathways.
Another key news theme is the company’s CNSide Diagnostics, LLC subsidiary and the CNSide® CSF Assay Platform. Press releases describe new state laboratory licenses, national coverage agreements with major payors, and real-world utilization metrics for the CNSide cerebrospinal fluid Tumor Cell Enumeration test used in managing leptomeningeal metastases.
Investors following PSTV can also expect announcements on financing and listing matters, such as public offerings of common stock and warrants, purchase agreements with institutional investors, and updates on Nasdaq listing compliance related to minimum bid price and equity standards. Corporate governance items, including proxy statements and stockholder meeting results, appear in both news and SEC filings.
This news page aggregates these updates so readers can track Plus Therapeutics’ clinical milestones, diagnostic platform expansion, regulatory communications, and capital markets events in one place. For those researching PSTV, it provides context on how the company is advancing its CNS cancer programs and managing its public company obligations over time.
Plus Therapeutics presented an update on the ReSPECT-GBM Phase 1/2 clinical trial for Rhenium (186Re) Obisbemeda in recurrent glioblastoma at the 2024 Congress of Neurological Surgeons Annual Meeting. Key highlights include:
- 42 patients enrolled, with 19 treated at the recommended Phase 2 dose
- Favorable safety profile observed
- Mean Phase 2 absorbed dose was 300 Gy
- 89% of patients exceeded the minimal dose threshold of 100 Gy
- Statistically significant reduction in tumor volume rate change for tumors receiving >100 Gy absorbed dose
- Trial expanded to two new sites at leading U.S. academic medical centers
The data suggests continued safety and potential efficacy of Rhenium (186Re) Obisbemeda in patients with recurrent glioblastoma, supporting its advancement as a promising therapeutic option.
Plus Therapeutics (Nasdaq: PSTV) will present new interim data from its ReSPECT-GBM Phase 2 trial at the 2024 Congress of Neurological Surgeons Annual Meeting. The presentation, titled "Treatment of Recurrent Glioblastoma (rGBM) via Convection Enhanced Delivery (CED) with Rhenium (186Re) Obisbemeda (Rhenium-186 Nanoliposome, 186RNL): ReSPECT-GBM Phase 2 Trial Update," will be given by Dr. John Floyd on September 30, 2024. This showcases progress in Plus Therapeutics' program for recurrent glioblastoma, using targeted radiotherapeutics with advanced platform technologies for central nervous system cancers.
Plus Therapeutics (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel.
Key details:
- Marc H. Hedrick, M.D., President and CEO of Plus Therapeutics, will present a corporate overview
- The presentation will be available on-demand starting September 9, 2024, at 7:00 AM ET
- A replay will be accessible for 90 days on the company's website
- Management will be available for one-on-one meetings during the conference
Investors and interested parties can access the webcast and register for the conference through the provided links.
Plus Therapeutics (PSTV) reported Q2 2024 financial results and business highlights. Key points:
- Presented positive interim ReSPECT-LM Phase 1 data for Rhenium (186Re) Obisbemeda in leptomeningeal metastases
- Reported positive topline results for CNSide diagnostic in FORESEE trial
- Cash balance of $8.4 million as of June 30, 2024
- Recognized $3.0 million in grant revenue in H1 2024
- Net loss of $6.2 million, or $(1.15) per basic share in H1 2024
The company plans to complete the ReSPECT-LM Phase 1 single administration trial, initiate a multiple administration trial, and obtain IND approval for a Phase 1/2 trial in pediatric ependymoma and high-grade glioma.
Plus Therapeutics (NASDAQ: PSTV) presented positive results from the FORESEE study of its CNSide platform for diagnosing and managing leptomeningeal metastases (LM) at the 2024 SNO/ASCO CNS Metastases Conference. The trial, involving 39 patients with breast or non-small cell lung cancer, met its primary and secondary endpoints. Key findings include:
- CNSide influenced treatment decisions in over 90% of cases
- 80% sensitivity in detecting tumor cells compared to 29% for CSF cytology
- Identified actionable mutations, influencing 24% of therapeutic selections
- High specificity with no false positives
These results suggest CNSide's potential for earlier LM diagnosis and improved patient management.
Plus Therapeutics (Nasdaq: PSTV) presented positive interim data from its ReSPECT-LM Phase 1 trial of Rhenium (186Re) Obisbemeda for leptomeningeal metastases at the 2024 SNO/ASCO CNS Metastases Conference. The study showed continued feasibility and safety with up to 44 mCi of intrathecal treatment. Key highlights include:
- No dose-limiting toxicities through cohort 4
- Linear increase in absorbed radiation dose
- Mean reduction of 53% in CSF circulating tumor cells at 28 days post-treatment
- Median overall survival of 12 months
- Majority of adverse events were mild or moderate
The FDA has granted Fast Track and Orphan Drug designations for this treatment. The trial is currently enrolling in Cohort 5 and is partially funded by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas.
Plus Therapeutics (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, has announced its plans to release second quarter 2024 financial results on August 14, 2024, after market close. The company will host a conference call and webcast at 5:00 p.m. ET on the same day to discuss the financial results and provide a corporate update.
Investors and interested parties can access the webcast through the provided link or pre-register for the conference call. A replay of the call will be available on the company's website in the 'For Investors' section, and the webcast will remain accessible for 90 days following the live call.
Plus Therapeutics (Nasdaq: PSTV) will present new data on its Leptomeningeal Metastases (LM) programs at the 2024 SNO/ASCO CNS Metastases Conference. The company will host a symposium on 'Emerging Novel Diagnostic and Therapeutic Approaches for Leptomeningeal Metastases' on August 8. Key presentations include:
1. Phase 1 dose escalation study of Rhenium (186Re) Obisbemeda for LM treatment
2. Radiation absorbed dose to spinal cord in LM therapy using beta-emission radiopharmaceuticals
3. CSF Tumor Cell detection for clinical management of breast and lung cancer patients with LM
4. CNSide CSF Tumor Cell detection platform for LM disease management
These presentations highlight Plus Therapeutics' progress in both therapeutic and diagnostic approaches for LM, a challenging area in central nervous system cancers.
Plus Therapeutics (Nasdaq: PSTV), a clinical-stage pharmaceutical firm, announced that Dr. Melissa Moore, VP of Clinical Research and Development, will present at the Gordon Research Conference on July 8, 2024, in Newry, Maine. The presentation, scheduled for 11:30 a.m. EDT, will cover data from the ReSPECT-GBM and ReSPECT-LM studies. These trials evaluate the company's lead radiotherapeutic, rhenium (186Re) obisbemeda, for treating recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Plus Therapeutics focuses on developing targeted radiotherapeutics for CNS cancers, utilizing advanced platform technologies and strategic partnerships for potential product commercialization.
Plus Therapeutics has appointed Dr. Greg Fuller as Vice President of Medical Affairs and Medical Director. Fuller, formerly with The University of Texas MD Anderson Cancer Center, will help implement the CNSide® cerebrospinal fluid cancer diagnostic portfolio. Plus also received a $3.3 million advance payment from CPRIT for its leptomeningeal cancer radiotherapeutic program, part of a $17.6 million award from 2022. CNSide, used in the ReSPECT-LM clinical trial, is expected to launch commercially by Q4 2024. CNSide is over 90% sensitive for detecting leptomeningeal metastases, potentially expanding the market for Plus' lead candidate, rhenium (Re186) obisbemeda. The $3.3M funding will support ongoing clinical developments and validation of CNSide. Fuller received option awards for 13,116 shares of Plus stock, vesting over four years.
FAQ
What is the current stock price of Plus Therapeutics (PSTV)?
What is the market cap of Plus Therapeutics (PSTV)?
